TPP1 and infantile neuronal ceroid lipofuscinosis: For example, the recombinant human tripeptidyl peptidase 1 enzyme (cerliponase alfa) has been delivered as the first approved therapy via ICV infusion to treat patients with neuronal ceroid lipofuscinosis type 2 (CLN2) [24].